Since co-repressors are not mutated and have aberrant activity in cancer, they are sufficient and logical molecular targets that may engage terminal differentiation genes for p53 cell cycle exits7,89,99,100,102,105,108–111 (Table 2; Fig. 5c, d). The gene discussed is TP53; the disease is cancer.